Patients in the U.S. now have access to the first generic GLP-1 treatment approved for weight loss as Teva has launched its copycat of Novo Nordisk’s injected Saxenda (liraglutide). The compound, ...
US FDA review finds no evidence linking GLP-1 receptor agonists in popular medicines like Wegovy and Zepbound to an increased risk of suicidal thoughts or behaviour ...
By Mariam Sunny Jan 13 (Reuters) - The U.S. health regulator asked drugmakers on Tuesday to remove warnings about a potential risk of suicidal thoughts from widely used GLP-1 weight-loss drugs, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results